Elan Corporation, plc ELN today announced completion of the
separation of a substantial portion of its drug discovery business (the
Prothena Business) into a new independent, publicly traded company,
Prothena Corporation plc (Prothena). Prothena, which is incorporated in
Ireland, today commenced trading on the NASDAQ Global Market under the
ticker symbol “PRTA”.
Under the terms of the demerger, Elan shareholders on the register on
December 14, 2012, the record date, received 1 Prothena ordinary share
for every 41 Elan ordinary shares or ADSs held. In addition a wholly
owned subsidiary of Elan subscribed $26 million and received Prothena
shares representing 18% of the total outstanding ordinary shares of
Prothena (as calculated immediately following the subscription
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in